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Metastatic renal-cell cancer (mRCC) is considered incurable,
and systemic therapy is the foundation of patient manage-
ment. Historically, hormonal therapy was used for palliation
of symptoms but had little anti-cancer effect [1]; cytotoxic
chemotherapy is beneficial for only a small proportion of pa-
tients [2–7]. Immunotherapy, generally interferon-alpha
(IFNa), was standard treatment until 2005, when it was re-
placed by the first inhibitor of the vascular endothelial growth
factor receptors (VEGFRs), sunitinib [8]. Since then, another
six agents which target either the VEGF or the mammalian
target of rapamycin (mTOR) pathways have been developed
and approved for use in advanced RCC [9–15]. Notably, cytore-
ductive nephrectomy was proven in two randomised trials to
improve survival in combination with IFN, compared with
drug treatment alone [16]. Despite a significant change in
the systemic agents utilised in mRCC, this has remained an
integral aspect of the treatment approach.
The prognosis for patients with mRCC has improvedmark-
edly with the introduction of agents targeting cell signalling
pathways [17,18]. The expected survival time for an individual
patient can be highly variable, but it is standard practice to
categorise patients with mRCC into prognostic groups, origi-
nally defined by the Memorial Sloan Kettering Cancer Center
(MSKCC) in the immunotherapy era of treatment [19]. This
model, which uses clinical and pathological factors to group
patients into favourable, intermediate and poor-risk groups,
has now been updated and validated in patients treated with
VEGFR–tyrosine kinase inhibitors (VEGFR–TKIs) [20] and is an
important consideration in the current standards of care.
The treatment algorithm for mRCC in 2013 includes seven
targeted agents and cytokine therapy, used in a sequential
fashion [21]. This algorithm is becoming increasingly complex
as clinical trials attempt to define the optimal treatment reg-
imen to improve progression-free and overall survival and re-
sponse rates, and to preserve quality of life. Combinations oftargeted drug therapy remain experimental; to date, no com-
bination has proved to be superior to monotherapy, and it is
frequently poorly tolerated [22].
This educational chapter will summarise the treatment
algorithm for advanced RCC and will provide details on how
treatments may be individualised within the algorithm. The
potential impact of new agents, future trial results and devel-
opments in translational research in mRCC will also be
discussed.
2. First-line therapies
It has long been recognised that some patients with mRCC
have indolent disease biology, and a period of observation is
often recommended when metastatic disease is first diag-
nosed. This approach has clear advantages – it allows assess-
ment of the pace of metastatic disease and can spare patients
the chronic toxicities associated with drug therapy, as well as
having health economic benefits – but there is only prelimin-
ary, retrospective evidence for its safety, and it is not clear for
which patients this strategy is most suitable [23]. A deferred
drug treatment approach in mRCC is currently being evalu-
ated in a prospective, observational study [24].
Immunotherapy has largely been replaced by targeted
therapies, but is considered an acceptable treatment option
in patients with low- or intermediate-risk disease; IFN in par-
ticular remains a relevant therapy in those countries with re-
stricted or no access to high-cost drugs. A 2005 systematic
review of IFN reported modest improvements in disease con-
trol rates, 1-year and overall survival compared with non-
immunotherapy controls, with approximately 13% of patients
achieving a partial or complete response [25]. Notably, high-
dose IL-2 (HD IL-2) produces durable response rates in a small
proportion of patients with mRCC [26,27]; most recently, the
‘SELECT’ trial of HD IL-2 found an improved response rate
(29%) compared with historical results which was attributed
to improved patient selection on clinical and pathologicall.: +44 207
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ated with long-term remissions in mRCC, but its potential for
severe toxicity and efficacy in a restricted, molecularly unde-
fined subgroup of patients has limited its clinical application.
Sunitinib and sorafenib are kinase inhibitors with multiple
targets, including the VEGF-receptors [29–31]. They were the
first drugs developed in the VEGFR–TKI class of agents; hence
they are associated with extensive clinical experience in
mRCC. There is a stronger evidence base for sunitinib as
first-line therapy. Sunitinib was compared with IFN in a ran-
domised phase III trial and resulted in a statistically superior
response rate (47% versus 12%), and progression-free survival
(PFS) time (median 11 months versus 5 months) [8]. The med-
ian overall survival time was 26.4 months for sunitinib com-
pared to 21.8 months for IFN-treated patients, which only
became significant when those patients who crossed over
from IFN to sunitinib were excluded from the analysis [32].
The efficacy of sunitinib was confirmed in a large safety study
which enrolled a broader population of patients, including el-
derly patients, those with poor-risk disease as defined by the
MSKCC criteria and thosewith non-clear-cell RCC [33]. Sorafe-
nib was also compared with IFN treatment in 189 untreated
mRCC patients in a randomised phase II trial [34]. Although
the median PFS times for sorafenib and IFN were similar
(approximately 5.7 months), sorafenib was interpreted as
having superior clinical benefit because of improved response
rates, tolerability and quality-of-life assessments.
Pazopanib was developed as a multi-targeted kinase inhib-
itor with improved potency against VEGFR-2, thought to have
the most biological relevance of the VEGF receptors in clear-
cell RCC [35]. It was registered in the first-line treatment set-
ting on the basis of improved progression-free and overall
survival in patients who were either treatment-naı¨ve or who
had received prior cytokine therapy, in a placebo-controlled
trial [36]. Preliminary results of the COMPARZ study, compar-
ing sunitinib and pazopanib in first-line treatment for mRCC,
were presented in abstract form at the European Society of
Medical Oncology (ESMO) meeting in 2012 [37]. The median
PFS for pazopanib was 8.4 months and 9.5 months for suniti-
nib, and interim OS times were 28.4 months and 29.3 months,
respectively. This was a non-inferiority study, and although it
has been criticised for its design, it would appear to confirm
anecdotal experience that the two drugs are equivalent in
efficacy, and this is reflected in current clinical practice guide-
lines [21,38].
The intravenous monoclonal antibody to VEGF, bev-
acizumab, is an alternative first-line treatment for patients
with favourable or intermediate-risk mRCC. Two phase III tri-
als combined bevacizumab with IFN and randomised patients
to the combination or to IFN alone [12,13]. Both reported im-
proved response rates (combined analysis 28.4% versus
12.9% [18]) and PFS times (8.5 months versus 5.2 months
[12]) and 10.2 months versus 5.4 months [13]) over IFN mono-
therapy. Overall survival was not significantly improved by
bevacizumab in either study, perhaps because of subsequent
anti-VEGF systemic treatment in many patients.
Temsirolimus is an inhibitor of the mTOR complex 1 and is
the only systemic agent to be studied specifically in a poor-
prognosis group of patients with mRCC. A phase III trial of
temsirolimus or IFN or the combination enrolled treatment-naı¨ve patients who met three of six adverse risk features: lac-
tate dehydrogenase (LDH) level of more than 1.5 times the
upper limit of normal, haemoglobin level below the lower lim-
it of normal, elevated calcium, time from initial diagnosis of
RCC to randomisation of less than 1 year, a Karnofsky perfor-
mance status of 60 or 70, or metastases in multiple organs
[15]. Notably, approximately a third of the patients in this
study had not had a nephrectomy. Median PFS in the temsi-
rolimus group was 5.5 months and median OS 10.9 months,
and temsirolimus is therefore a standard of care in this group.3. Second-line therapies
Accepted second-line treatments for mRCC are the VEGFR–
TKIs sorafenib, sunitinib, pazopanib and axitinib, and the oral
mTOR inhibitor everolimus. Frequently, the decision is influ-
enced by which first-line treatment the patient has received;
for example, there is evidence that sorafenib, sunitinib, paz-
opanib and axitinib have clinical activity after prior cytokine
therapy [10,11,33,39].
The main controversy exists in the decision between ever-
olimus and axitinib, when patients have been previously trea-
ted with a VEGFR–TKI. The RECORD-1 study compared
everolimus to placebo in previously treated patients [14,40].
This was not strictly a second-line trial only, but patients were
stratified by the number of previous VEGFR–TKI treatments;
in patients who had received only one prior VEGFR–TKI, the
median PFS for everolimus was 5.4 months, and 1.9 months
for placebo [41]. Similar results were reported for the analysis
of sunitinib- and sorafenib-treated patients. Two further tri-
als, including the large expanded access study of everolimus
(REACT), confirmed that everolimus has meaningful clinical
activity in anti-VEGF treatment-refractory patients [42,43].
The phase III AXIS study randomised patients who had re-
ceived prior sunitinib, cytokine, bevacizumab or temsirolimus
to second-line treatment with axitinib or sorafenib [11];
approximately two thirds of the 723 patients enrolled had
had first-line anti-VEGF treatment. Overall, PFS was in favour
of axitinib, with a median time of 6.7 months, compared to
4.7 months for sorafenib. This difference was less pro-
nounced, however, in patients who had received prior suniti-
nib or bevacizumab.
Results of the RECORD-3 study were presented in abstract
form in 2013, adding further support to the efficacy of a VEG-
FR–TKI:mTOR inhibitor algorithm [44]. This phase II trial ran-
domised patients to either first-line everolimus, followed by
sunitinib on progressive disease, or sunitinib followed by
everolimus. It was designed to prove non-inferiority of PFS
with first-line everolimus compared to sunitinib, but did not
with its primary end-point (median PFS for everolimus
7.85 months and for sunitinib 10.71 months). Preliminary OS
results suggest that the current algorithm of sunitinib in the
first line followed by everolimus is superior to the opposite se-
quence. These results do not resolve the issue of whether a
VEGFR–TKI or mTOR inhibitor is superior after failure of
first-line anti-VEGF treatment, but add to the evidence base
regarding optimal sequencing of systemic agents in mRCC.
With respect to the former question, the efficacy of temsirol-
imus and sorafenib were compared in patients previously
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the ESMOmeeting in 2012 [45]. Both drugs produced a median
PFS of approximately 4 months, but overall survival was sig-
nificantly better for sorafenib (16.6 months versus
12.4 months for temsirolimus). These results seem to indicate
that although VEGF followed by mTOR inhibition is an effica-
cious strategy, everolimus and temsirolimus are not necessar-
ily interchangeable, perhaps owing to their differing
pharmacokinetics [46,47].
4. Factors which guide treatment selection
It is clear that multiple choices now exist for the first- and
second-line treatment of patients with mRCC. Currently, the
choice of agent is largely determined by the licensed indica-
tion for the drug, which in turn depends on the clinical con-
text in which the drug’s registration trial took place.
However, as the clinical trial portfolio in mRCC has expanded
to include more sophisticated trial designs, and eligibility cri-
teria broadened, the decision about optimal treatment has be-
come increasingly complex. To further complicate the issue,
there are few direct comparisons between the various agents
[11,37,45] and it is therefore difficult to confidently identify a
superior drug for a given clinical situation. Nonetheless, there
are a number of factors which enable selection of treatment
to some degree, and also research initiatives aiming to move
the field towards an individualised approach to treatment.
4.1. Disease and patient factors
Clinical risk models such as the MSKCC model provide a for-
malised assessment of those features which indicate less
favourable biology in mRCC [19]. This model, now validated
by Heng and colleagues in patients treated with VEGFR–TKIs
[20] includes parameters such as haematological, biochemical
and performance status to categorise patients into favour-
able-, intermediate- and poor-risk groups, each with a distinct
survival time. However, risk stratification does not predict re-
sponse to treatment; a nomogram which utilises 11 pre-treat-
ment clinical and pathological variables predicts a 12-month
PFS with first-line sunitinib treatment [48]. A more compre-
hensive model such as this may improve decision-making
for individual patients, but it has not been validated. Recently,
an analysis of factors influencing survival in sunitinib-treated
patients was published, and this confirmed previously pub-
lished findings but also identified independent predictors of
long-term survival, including ethnic origin, bone metastases
and adjusted calcium level [49].
Features of the disease are frequently used in clinical prac-
tice to guide selection of treatment. The most obvious exam-
ple is the histological subtype of RCC. Most phase IIII trials in
mRCC enrolled only patients with the clear-cell subtype, but
approximately 25% of patients will have non-clear-cell histol-
ogy, most commonly papillary or chromophobe subtypes. The
optimal treatment for these groups has not yet been defined;
on balance it appears that the targeted agents currently in use
have activity in non-clear-cell RCC, but that the activity may
be reduced compared to that in patients with clear-cell mRCC.
However, there is evidence from some large therapeutic series
that temsirolimus, everolimus and sunitinib have similar effi-cacy in patients with clear-cell and non-clear-cell disease
[33,50,51]. Considering the papillary subtype alone, the re-
ported range of PFS on VEGF-targeted agents varies consider-
ably (1.6–11.9 months) [52–55], but studies have not always
analysed type 1 and type 2 papillary patients (in whom there
is clearly distinct biology) separately. Response rates in the
range of 12–40% and PFS times from 4 to 14 months have been
reported for sunitinib, sorafenib, temsirolimus or everolimus
in chromophobe mRCC [52,53,55–59], although not always in
the first- or second-line setting. The presence of sarcomatoid
differentiation, which can occur in any histological subtype,
adds a considerable degree of uncertainty as to the best
choice of systemic agent (for a comprehensive review, see
[60]), because the molecular driver of sarcomatoid change is
unknown, the degree to which it is present is highly variable,
and there are limited prospective therapeutic studies. Based
on available data, the activity of sorafenib and sunitinib
seems to be superior to that of cytotoxic chemotherapy, but
outcomes are modest at best with these agents [61–64].
The burden and pattern of metastatic disease further
influences treatment choice. Patients who are symptomatic
from either a high volume of metastatic disease or disease
in critical viscera are probably best served by a multi-targeted
kinase inhibitor, because these agents are more likely to
cause tumour regression than mTOR inhibitors. Response
rates to sunitinib and pazopanib as first-line treatment, and
axitinib as second-line treatment, can be as high as 40%
[8,10,11], whereas reported response rates for temsirolimus
and everolimus monotherapy are 610% [14,15]. Decisions
about systemic treatment in those with specific metastatic
disease sites such as the brain are complex; frequently,
integration of local therapies is required, and there are no
prospective data on which to base treatment recommenda-
tions. In the example of brain metastases, sunitinib has the
strongest evidence of clinical activity [65–68].
Patient factors that should be considered when choosing
systemic treatment for mRCC include their co-morbidities,
age, expectations of and preferences for treatment and social
and pragmatic issues such as their ability to attend the hospi-
tal. The VEGFR–TKIs have multiple additional targets, and the
relative potency of these agents for different targets results in
differing side-effect profiles. The toxicities associated with
specific agents are described in detail in a separate educa-
tional chapter, but these must be balanced against baseline
organ dysfunction – including cardiovascular, endocrine, hep-
ato-biliary and haematological problems – when therapy is
chosen.
The effect of advanced age on the safety and efficacy of
targeted agents is now under careful evaluation, with the rec-
ognition that patients treated in drug development trials are
not representative of the mRCC population encountered in
the clinic. A combined analysis of 4684 patients treated with
sorafenib in six clinical trials and two expanded access pro-
grammes was recently published [69], including 599 patients
aged over 75 years. The authors reported that tolerability of
sorafenib monotherapy was similar between the four age
groups analysed, but those in the oldest group had a shorter
duration of treatment (median 3.1 months) compared to
those aged between 55 and 75 (median 4.0–4.2 months). Nota-
bly, 17% of patients aged 65–75 and 8% of those over 75 re-
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12 months. Likewise, pooled retrospective data from approxi-
mately 1000 patients treated with sunitinib indicate that its
efficacy is similar in those under and over the age of 70 [70].
The overall rate of treatment-related adverse events was also
comparable between the two age groups, although particular
side-effects – such as fatigue, anorexia and weight loss,
cough, peripheral oedema and haematological abnormalities
– were noted to be higher in the older age group. The sunitinib
expanded access study included a significant proportion of
patients over the age of 65 (approximately 1/3 of the study
population, 1000 patients); the response rate of 17%, median
PFS of 11.3 months and median OS of 18.2 months were the
same as in the overall study population [33]. Finally, there is
evidence that everolimus has a similar efficacy and safety
profile in those over 65 years of age, from a retrospective anal-
ysis of the RECORD-1 study [71]. In summary, these data sug-
gest that chronological age alone should not be an influential
factor in treatment selection, rather that co-morbidities and
geriatric syndromes such as polypharmacy may need more
careful assessment and weighting in the older patient.
Preservation of quality of life is an important therapeutic
goal in mRCC. This can be difficult to achieve, because all tar-
geted agents are associated with at least some degree of tox-
icity which is chronic. Arguably, patients are best placed to
make decisions about treatment based on toxicity and quality
of life, but the latter has not been rigorously studied and/or
reported in clinical trials. For this reason, the PISCES (patient
preference study between first-line pazopanib and sunitinib)
trial, presented in abstract form in 2012 [72], has been com-
mended for its novel design. Patients were randomised to re-
ceive either drug for 10 weeks, followed by a 2-week washout
period before switching to the second drug. A clear patient
preference for pazopanib over sunitinib was displayed,
although the different drug schedules and timing of quality
of life assessments complicate the analysis and in particular
may have disadvantaged the evaluation of sunitinib. A similar
study design is employed in the TAURUS trial, a phase II trial
evaluating patient preference for the potent VEGFR–TKI tivo-
zanib for 12 weeks followed by sunitinib for 12 weeks, or vice
versa (NCT01673386). The phase III SWITCH trial will evaluate
sunitinib followed by sorafenib and the opposite sequence,
but the primary end-point is PFS (NCT00732914). Both of these
trials will be conducted in the first-line treatment setting.
4.2. Predictive biomarkers in mRCC
Predicting sensitivity to systemic therapy is the fundamental
prerequisite for the delivery of personalised treatment in
mRCC. Response to first-line targeted agents appears to be
an important indicator of longer-term outcome, with a retro-
spective analysis demonstrating that PFS below and above an
arbitrary threshold of 6 months during first-line treatment
was an independent predictor of overall survival (median OS
12.1 months versus 46.8 months, respectively, P < 0.0001)
[73]. However, when anti-VEGF treatments are used in a first-
and second-line sequence, response to the first does not pre-
dict response to the second [74,75]; this is somewhat counter-
intuitive, but is perhaps further evidence that drug response
is probably the result of complex interaction between multi-ple tumoural, pharmacodynamic and pharmacokinetic
factors.
Clinical parameters indicative of response to VEGF-tar-
geted treatments may help to limit patients’ exposure to the
drug in the absence of benefit. Drug-induced hypertension
is a compelling example of this. A retrospective, pooled anal-
ysis of data from four clinical trials of sunitinib treatment in
patients withmRCC found that hypertensive patients, defined
by systolic blood pressure and diastolic blood pressure to a
lesser degree, had improved clinical outcomes [76]. In the
AXIS trial, diastolic blood pressure ofP90 mmHg at 12 weeks
was significantly associated with improved overall survival in
both the axitinib (20.7 months versus 12.9 months) and
sorafenib (20.9 months versus 14.8 months) arms [75], con-
firming an earlier correlation of axitinib efficacy and diastolic
blood pressure in phase II studies [77]. A prospective, random-
ised assessment of the efficacy of axitinib dose up-titration is
currently under way (NCT00835978).
The utility of hypertension in treatment selection for an
individual patient is debatable; the identification of a molecu-
lar marker that is predictive of response a priori is a key goal
of translational research in mRCC. At this time, no such bio-
marker has been established. In patients treated with anti-
VEGF agents, biomarker development efforts based on defi-
cient tumoural von Hippel Lindau (VHL) gene function and
resultant angiogenesis, the central abnormalities in clear-cell
RCC, have been unsuccessful, perhaps because the pathogen-
esis involves stromal rather than tumour cells. However,
promising discoveries have been made in relation to single-
nucleotide polymorphisms (SNPs), inherited variants in DNA
sequence, which may influence the biology underlying drug
sensitivity. Several retrospective analyses correlated SNPs in
VEGF or VEGF-receptors and drug metabolism genes (includ-
ing CYP3A5, CYP1A1, ABCB1 and 2 and NR1I3) with sunitinib
efficacy or toxicity [78–80]; a fourth study found that an SNP
in VEGF was associated with the development of sunitinib-in-
duced hypertension, but no single SNP predicted variation in
clinical outcome [81]. A prospective observational study in
which all patients received sunitinib demonstrated a signifi-
cant relationship between polymorphisms in VEGFR3 and
CYP3A5*1 with reduced sunitinib response and greater toxic-
ity, respectively [82]. Furthermore, SNPs in angiogenesis or
drug exposure genes – including IL-8 and HIF1A – may have
predictive value; the IL-8 2767TT and the HIF1A 1790AG vari-
ant genotypes were associated with reduced PFS times com-
pared to wild-type genotypes, in patients treated with
pazopanib compared to placebo [83]. This finding has biolog-
ical plausibility in that IL-8 has been identified as a potential
mediator of an angiogenic escape and thus resistance to anti-
VEGF treatment [84]. High plasma concentration of IL-8 has
also been shown to predict for shorter PFS in patients treated
with pazopanib in a retrospective analysis of the phase III
pazopanib-versus-placebo trial, whereas high concentration
of IL-6 predicted PFS benefit from pazopanib [85]. The major
issue with the studies relating to SNPs is that they have each
evaluated non-overlapping sets of SNPs, and no dominant
polymorphism or one common to different anti-VEGF treat-
ments has emerged [86]. Additionally, the frequency of iden-
tified SNPs is often low, and the biological processes which
underpin the relationship between SNPs and clinical out-
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mal tissue to the drug or altered drug metabolism, are not de-
scribed. However, if validated, germline genetic variants may
be very useful in drug selection, and may be particularly rele-
vant to efficacy and safety of drugs between different ethnic
groups affected by RCC.
Activation of the mTOR signalling pathway is extensively
demonstrated across grades, histological subtypes and tu-
mour sites in RCC, and alteration of some of its components
has been shown to confer a worse prognosis [87,88]. Further-
more, there is preliminary evidence that somatic mutations
in genes such as mTOR, or the tumour suppressor tuberous
sclerosis genes (TSC1 and TSC2) causing gain or loss of func-
tion, respectively, are associated with long-term response to
mTOR inhibitors [89]. Serum LDH may have a prognostic –
and possibly predictive – role in patients treated with temsi-
rolimus or everolimus [40,90,91].
Evidently, the biological relationship between tumour and
drug response is multifaceted, and recent work using ad-
vanced genomic technology has added further layers of com-
plexity to the picture. Exome sequencing of multiple tumour
regions from a small number of patients with advanced
clear-cell RCC revealed spatially separated somatic mutations
in a large number of low-frequency tumour suppressor genes;
the identification of only a small number of genes altered
ubiquitously throughout tumour regions, and the clonal hier-
archy of the mutations, points to early divergent evolution of
these tumours [92]. It is therefore contended that a single
biopsy will not represent the mutational range of the entire
tumour, and that such intra-tumour heterogeneity will hinder
biomarker discovery efforts [93,94]. It is widely recognised
that there is a critical need to identify biomarkers predictive
of response [17,95], and this is reflected by the now consider-
able number of biomarker development programmes in RCC
(reviewed in [96]). Increasingly, therapeutic clinical trial de-
sign includes a tissue collection component to facilitate sci-
entific research.5. Ongoing trials and emerging therapies
The clinical trial portfolio in mRCC continues to expand rap-
idly, and there are several ongoing trials that may alter the
current treatment algorithm. On the other hand, there is de-
bate as to how significantly emerging agents will improve
upon current standards. For example, a phase III trial rando-
mising patients to the potent pan-VEGFR inhibitor tivozanib
or sorafenib found a PFS benefit in favour of tivozanib
(11.9 months versus 9.1 months) but no difference in overall
survival between the two drugs [97]. The AGILE study, com-
paring axitinib and sorafenib in first-line treatment of mRCC,
also found improved PFS and response rates for axitinib, but
did not meet its statistical primary end-point of PFS [98]. Both
of these trials could be criticised for their use of sorafenib as a
comparator, and the data are still immature, but in a broader
view may suggest that improvements in clinical outcomes
with the classes of agents currently available have reached
a plateau.
For this reason there is much interest in a new class of sys-
temic agents, the immune checkpoint inhibitors. An immunecheckpoint is an inhibitory mechanism whose role is to regu-
late T-cell response to pathogens and to limit autoimmunity.
Tumours can exploit these pathways to evade destruction by
the immune system, and two immune checkpoint molecules
have therapeutic relevance: the cytotoxic T-lymphocyte anti-
gen 4 (CTLA-4) and the programmed death-1 (PD-1) receptors.
Ipilimumab is a monoclonal antibody inhibiting the CTLA-4
receptor that improves survival in metastatic melanoma
[99,100]. In RCC, the most highly developed of the checkpoint
inhibitors is nivolumab (BMS-936558, MDX-1106), a monoclo-
nal antibody against the PD-1 receptor. PD-1 is an inhibitory
co-receptor that is expressed on activated T cells, particularly
regulatory T cells, as well as activated B cells and natural kill-
er cells [101]. Its two ligands, PD-L1 and PD-L2, are up-regu-
lated widely in response to inflammation; along with
activated B, T, myeloid and dendritic cells, PD-L1 is expressed
on a range of endothelial and epithelial cells [102]. As such,
the function of the PD-1 pathway appears to be in limiting
the activity of T cells in peripheral tissues during an inflam-
matory response [102]. The rationale for inhibition of this
pathway as anti-cancer therapy is strengthened by the obser-
vations that the PD-1:PD-L1 pathway is up-regulated abun-
dantly in human cancers, and that PD-1 is expressed on a
significant proportion of tumour-infiltrating lymphocytes
[103]. Expression of PD-1 in resected RCC appears to have
prognostic significance [104].
In 2012, a large phase I trial of nivolumab reported its effi-
cacy and safety results in patients with a range of previously
treated, solid tumour types [105]. Among 34 patients with
RCC, objective responses occurred in four of 17 patients
(24%) treated with a dose of 1 mg/kg and in five of 16 patients
(31%) treated with 10 mg/kg. At the time of publication, five of
eight evaluable patients had an objective response that lasted
1 year of more, and stable disease lasting at least 24 weeks
was observed in an additional nine patients (27%). Common
treatment-related adverse effects were fatigue, rash, diar-
rhoea, pruritis, anorexia and nausea, but these were usually
low-grade; however, drug-induced pneumonitis occurred in
3% of patients and was fatal in three patients (1%). Nivolumab
is currently being assessed in a phase III trial as second-line
treatment against everolimus, in patients with mRCC previ-
ously treated with one or two anti-VEGF systemic treatments
(NCT01668784), and similar anti-PD-1 antibodies are in
development.
These encouraging early results come with the promise of
a predictive biomarker. In the phase I study described, PD-L1
tumour expression was assessed by immunohistochemistry
on pre-treatment tumour specimens from 42 patients; of 17
patients with PD-L1-negative tumours, none had an objective
response, and nine of 25 patients (36%) with PD-L1-positive
tumours experienced an objective response (P = 0.006). How-
ever, these results require reproduction and validation in
other clinical settings. For example, as PD-L1 expression ap-
pears to be closely associated with the presence of tumour-
infiltrating lymphocytes and secretion of IFN-gamma [106],
the effect of multiple prior treatments is uncertain, and the
prognostic versus the predictive power of PD-L1 expression
must be determined [101].
Anti-PD-L1 agents target the same axis, and there are now
two early reports of their efficacy. Theoretically, blockade of
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prove the safety and tolerability profile compared with anti-
PD-1 antibodies. In a phase I study, 17 patients with mRCC
were treated with the anti-PD-L1 antibody BMS 93-6559
[107]. Two patients (12%) had an objective response, one of
which lasted 17 months, and a further seven patients (41%)
remained stable for more than 24 weeks. A second phase I
trial enrolled a larger cohort of RCC patients and preliminary
results were presented at the American Society of Clinical
Oncology (ASCO) meeting in 2013 [108]; 53 patients with
mRCC, the majority of whom had received previous systemic
treatment, received MPDL3280A, an engineered human
monoclonal antibody to PD-L1. Notably, both rapid responses
and prolonged stability were observed: the response rate was
13%, and 32% of patients achieved stable disease lasting long-
er than 24 weeks. This treatment was reportedly well toler-
ated and differed in its side-effect profile from the anti-PD-1
antibodies; in particular, grade 3 or higher pneumonitis did
not occur.
6. Conclusions
There are now multiple systemic agents available for use in
mRCC, which, particularly when used sequentially, extend
the lives of patients and frequently provide effective pallia-
tive care. The ever-increasing repertoire of drugs for this
condition make decision-making for the individual patient
complex. In the absence of a predictive molecular biomarker,
treatments are selected using a combination of variables,
including the licensed indication of the drug, which in turn
can influence funding arrangements, and clinico-pathologi-
cal factors relating to the patient and the disease biology.
The algorithm will be further refined as research into the
optimal sequence of treatment, and treatments for smaller
patient groups such as those with non-clear-cell mRCC, is
completed. Statistically, the currently available drugs result
in clinical benefit for approximately 1 year at best, but clini-
cal experience suggests that the outcome for each patient is
highly variable. This emphasises the need for improved
understanding of mechanisms of resistance and, further-
more, prediction of drug sensitivity or resistance on an indi-
vidual level. A large number of biomarker initiatives have
received high-level funding, and clinical trial design is
adapting to address translational questions. The develop-
ment of novel agents, such as immunostimulatory antibod-
ies, is a further reason for optimism, with drugs such as
anti-PD-1 antibodies offering the possibility of long-term dis-
ease control.
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